Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674801 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1CYP2A6TDP1TSHR | |
| SCHEMBL31001023 | 0.88 | CYP1A2 (0.56) | CYP1A2ALDH1A1CYP2A6TDP1TSHR | |
| SCHEMBL15412761 | 0.83 | CYP1A2 (0.45) | CYP1A2ALDH1A1CYP2A6TDP1TSHR | |
| SCHEMBL1134728 | 0.79 | TSHR (0.41) | CYP1A2ALDH1A1CYP2A6TDP1TSHR | |
| SCHEMBL3731211 | 0.79 | CYP1A2 (0.47) | CYP1A2ALDH1A1CYP2A6TDP1TSHR | |
| SCHEMBL26437113 | 0.78 | CYP1A2 (0.55) | CYP1A2ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL7708643 | 0.76 | CYP1A2 (0.39) | CYP1A2ALDH1A1CYP2A6TDP1TSHR | |
| SCHEMBL10692403 | 0.76 | TDP1 (0.50) | CYP1A2ALDH1A1CYP2A6TDP1TSHR | |
| SCHEMBL26431811 | 0.76 | TSHR (0.46) | CYP1A2ALDH1A1CYP2A6TDP1TSHR | |
| SCHEMBL8889111 | 0.74 | CYP1A2 (0.43) | CYP1A2ALDH1A1CYP2A6TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905302-B2 | Prelithiation and method of manufacturing prelithiated anode using the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-02-20 | — | — | US | disclosed |
| CN-117233296-A | Method for non-targeted identification of trace organic pollutants in blood based on GC-QTOF-HRMS and application thereof | 广东工业大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20210347787-A1 | PRELITHIATION SOLUTION AND METHOD OF MANUFACTURING PRELITHIATED ANODE USING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2021-11-11 | — | — | US | disclosed |
| US-20140135359-A1 | METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES | MARTINEAU LOUIS C (CA) | 2014-05-15 | — | — | US | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1569652-A4 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| EP-1569652-A2 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | Pharmasset Ltd. (BB) | 2005-09-07 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | CYP1A2 1240/4885ALDH1A1 2325/4885CYP2A6 1327/4885 |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | CYP1A2 1415/4885ALDH1A1 2300/4885CYP2A6 1388/4885 |
| US-11905302-B2 | Prelithiation and method of manufacturing prelithiated anode using the same | MT-ND6, NOX4, NDUFS6 | CYP1A2 2636/4885ALDH1A1 1605/4885CYP2A6 1751/4885 |
| US-20140135359-A1 | METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES | UQCRC2, UQCRC1, TIMM50 | CYP1A2 1651/4885ALDH1A1 3040/4885CYP2A6 825/4885 |
| US-20210347787-A1 | PRELITHIATION SOLUTION AND METHOD OF MANUFACTURING PRELITHIATED ANODE USING THE SAME | THEM6, MT-ND6, NOX4 | CYP1A2 2885/4885ALDH1A1 1605/4885CYP2A6 1492/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | CYP1A2 810/4885ALDH1A1 645/4885CYP2A6 1101/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | CYP1A2 1161/4885ALDH1A1 2002/4885CYP2A6 1193/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | CYP1A2 592/4885ALDH1A1 14/4885CYP2A6 1024/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP1A2 1174/4885ALDH1A1 2341/4885CYP2A6 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.